Výsledky vyhledávání - "RET Fusion Positive"

Akademický článek

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Autor: Lee ATM, Ou SI

Publikováno v: Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 75-80 (2024)

Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Depar

Externí odkaz: https://doaj.org/article/239290dacf054e06a8a3547851c8fc4e

Zobrazit plný text záznamu

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

Autor: Novello, Silvia, Califano, Raffaele, Reinmuth, Niels, Tamma, Antonella, Puri, Tarun

Publikováno v: The Oncologist. 28:402-413

The objective of this narrative review is to summarize the efficacy and safety of available therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including in patients with central nervous system (CNS)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4320214acf4bc18a9598481627651b2
https://doi.org/10.1093/oncolo/oyac264

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Autor: Hannah M Davis, Jürgen Wolf, Keunchil Park, Boris Lin, Herbert H. Loong, Benjamin Solomon, Maurice Pérol, Fernando C. Santini, Victoria Soldatenkova, Alexander Drilon, Silvia Novello, Edurne Arriola, Koichi Goto, Aimee Bence Lin, C. Zhou, Yasir Elamin, Andreas Sashegyi

Publikováno v: Future Oncology. 17:763-773

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a14d0a19297afb403fa300a7dce7d6
https://doi.org/10.2217/fon-2020-0935

Zobrazit plný text záznamu

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

Autor: Hyun Ae Jung, Jong-Mu Sun, Cheol-In Kang, Jin Seok Ahn, Byeong-Ho Jeong, Sehhoon Park, Keunchil Park, Se-Hoon Lee, Yong-Pyo Lee, Myung-Ju Ahn, Yeonghee Eun

Publikováno v: European Journal of Cancer. 159:167-173

Background Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined. Herein, we pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f73023cfd5188b08a8d46a274ccc91f
https://doi.org/10.1016/j.ejca.2021.09.037

Zobrazit plný text záznamu

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial

Autor: Erminia Massarelli, Min Hua Jen, Jennifer Kherani, Valentina Boni, Vivek Subbiah, Aaron C. Tan, Anna Minchom, Elizabeth Olek, Lori J. Wirth, Caroline E. McCoach, Bruce G. Robinson, Lisa M. Hess

Publikováno v: Oncologist

Background LIBRETTO-001 is an ongoing, global, open-label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient-reported outcomes in patients with RET fusion–positive non-small cell lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a125a02252c31f143792561677be1457
https://doi.org/10.1002/onco.13976

Zobrazit plný text záznamu

Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer

Autor: Anthony N. Sireci, Yajun E Zhu, Naleen Raj Bhandari, Lisa M. Hess, Yimei Han

Publikováno v: Immunotherapy. 13:893-904

Aim: To describe outcomes of patients with rearraned during transfection ( RET) fusion-positive non-small-cell lung cancer (NSCLC) who received immune checkpoint inhibitor (ICI)-based treatments in the US. Patients & methods: Using de-identified Flat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9d56eb1c164258f34d84a310c9b63bd
https://doi.org/10.2217/imt-2021-0035

Zobrazit plný text záznamu

Advances in the treatment of RET-fusion-positive lung cancer

Autor: Oliver Gautschi, Georg Pall

Publikováno v: Lung Cancer. 156:136-139

Ten years ago, RET-fusions were discovered as oncogenic drivers and potential drug targets in approximately 1% of metastatic lung adenocarcinomas. Several multikinase inhibitors were tested in clinical trials, however, their antitumor activity was li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab0fcf47b088c17b9ff0208ae549e649
https://doi.org/10.1016/j.lungcan.2021.04.017

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání